Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Idasanutlin Monotherapy in Hydroxyurea-Resistant/Intolerant Polycythemia Vera
2017-000861-58Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of idasanutlin in polycythemia vera (PV) (2 cohorts), sponsored by Roche. Started Nov 2019; status: completed.
02
Drugs
idasanutlin
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2017-000861-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000861-58.